Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes

Background: SARS-CoV-2 is associated with a severe inflammatory response contributing to respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus disease 2019 (COVID-19). Methods: Tocilizumab (TCZ) efficacy on mortality and length of hospital stay was retrospect...

Full description

Bibliographic Details
Main Authors: Abeer Al-Baadani, Nazik Eltayeb, Eid Alsufyani, Salma Albahrani, Shareefah Basheri, Hawra Albayat, Enas Batubara, Sulafa Ballool, Ayed Al Assiri, Fahad Faqihi, Ali B. Musa, Asirvatham A. Robert, Nisreen Alsherbeeni, Fatehi Elzein
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Journal of Infection and Public Health
Subjects:
Tocilizumab
COVID-19
Hospital stay
Survival
SARS-CoV2
Interleukin-6
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034121001507

Internet

http://www.sciencedirect.com/science/article/pii/S1876034121001507

Similar Items